nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—Potassium Channel Antagonists—Nateglinide—type 2 diabetes mellitus	0.452	1	CiPCiCtD
Repaglinide—ABCC8—type 2 diabetes mellitus	0.0782	0.415	CbGaD
Repaglinide—KCNJ11—type 2 diabetes mellitus	0.0551	0.292	CbGaD
Repaglinide—PPARG—type 2 diabetes mellitus	0.0305	0.162	CbGaD
Repaglinide—ABCC8—Tolazamide—type 2 diabetes mellitus	0.0182	0.067	CbGbCtD
Repaglinide—ABCC8—Glimepiride—type 2 diabetes mellitus	0.0162	0.0597	CbGbCtD
Repaglinide—KCNJ11—Tolazamide—type 2 diabetes mellitus	0.0157	0.0579	CbGbCtD
Repaglinide—ABCC8—Glipizide—type 2 diabetes mellitus	0.0148	0.0546	CbGbCtD
Repaglinide—PPARG—Glipizide—type 2 diabetes mellitus	0.0148	0.0546	CbGbCtD
Repaglinide—KCNJ11—Glimepiride—type 2 diabetes mellitus	0.014	0.0516	CbGbCtD
Repaglinide—ABCC8—Gliclazide—type 2 diabetes mellitus	0.0138	0.0508	CbGbCtD
Repaglinide—CYP3A4—type 2 diabetes mellitus	0.0132	0.0699	CbGaD
Repaglinide—KCNJ11—Glipizide—type 2 diabetes mellitus	0.0128	0.0472	CbGbCtD
Repaglinide—KCNJ11—Gliclazide—type 2 diabetes mellitus	0.0119	0.0439	CbGbCtD
Repaglinide—ABCC8—Chlorpropamide—type 2 diabetes mellitus	0.0117	0.0432	CbGbCtD
Repaglinide—PPARG—Pioglitazone—type 2 diabetes mellitus	0.0117	0.0432	CbGbCtD
Repaglinide—ALB—type 2 diabetes mellitus	0.0115	0.0609	CbGaD
Repaglinide—PPARG—Rosiglitazone—type 2 diabetes mellitus	0.0108	0.0399	CbGbCtD
Repaglinide—ABCC8—Tolbutamide—type 2 diabetes mellitus	0.0105	0.0385	CbGbCtD
Repaglinide—KCNJ11—Chlorpropamide—type 2 diabetes mellitus	0.0101	0.0373	CbGbCtD
Repaglinide—KCNJ11—Tolbutamide—type 2 diabetes mellitus	0.00904	0.0333	CbGbCtD
Repaglinide—ABCC8—Nateglinide—type 2 diabetes mellitus	0.00889	0.0327	CbGbCtD
Repaglinide—PPARG—Nateglinide—type 2 diabetes mellitus	0.00889	0.0327	CbGbCtD
Repaglinide—KCNJ11—Nateglinide—type 2 diabetes mellitus	0.00769	0.0283	CbGbCtD
Repaglinide—ABCC8—Glyburide—type 2 diabetes mellitus	0.00601	0.0221	CbGbCtD
Repaglinide—KCNJ11—Glyburide—type 2 diabetes mellitus	0.00519	0.0191	CbGbCtD
Repaglinide—SLCO1B1—Pioglitazone—type 2 diabetes mellitus	0.00403	0.0148	CbGbCtD
Repaglinide—SLCO1B1—Rosiglitazone—type 2 diabetes mellitus	0.00372	0.0137	CbGbCtD
Repaglinide—SLCO1B1—Valsartan—type 2 diabetes mellitus	0.00329	0.0121	CbGbCtD
Repaglinide—ALB—Gliclazide—type 2 diabetes mellitus	0.0026	0.00956	CbGbCtD
Repaglinide—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.00236	0.00869	CbGbCtD
Repaglinide—ALB—Rosiglitazone—type 2 diabetes mellitus	0.00204	0.0075	CbGbCtD
Repaglinide—SLCO1B1—Losartan—type 2 diabetes mellitus	0.00189	0.00695	CbGbCtD
Repaglinide—ALB—Valsartan—type 2 diabetes mellitus	0.0018	0.00663	CbGbCtD
Repaglinide—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.00171	0.00628	CbGbCtD
Repaglinide—ALB—Nateglinide—type 2 diabetes mellitus	0.00167	0.00616	CbGbCtD
Repaglinide—ABCC8—penis—type 2 diabetes mellitus	0.00167	0.162	CbGeAlD
Repaglinide—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.00157	0.0058	CbGbCtD
Repaglinide—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.00152	0.0056	CbGbCtD
Repaglinide—PPARG—brown adipose tissue—type 2 diabetes mellitus	0.00134	0.13	CbGeAlD
Repaglinide—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.00124	0.00456	CbGbCtD
Repaglinide—ALB—Glyburide—type 2 diabetes mellitus	0.00113	0.00416	CbGbCtD
Repaglinide—PPARG—leg—type 2 diabetes mellitus	0.00108	0.104	CbGeAlD
Repaglinide—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00107	0.00395	CbGbCtD
Repaglinide—ALB—Losartan—type 2 diabetes mellitus	0.00103	0.00381	CbGbCtD
Repaglinide—PPARG—hindlimb—type 2 diabetes mellitus	0.000961	0.0931	CbGeAlD
Repaglinide—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.000957	0.00352	CbGbCtD
Repaglinide—CYP3A4—Glipizide—type 2 diabetes mellitus	0.000876	0.00322	CbGbCtD
Repaglinide—CYP2C8—Losartan—type 2 diabetes mellitus	0.000799	0.00294	CbGbCtD
Repaglinide—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.000692	0.00255	CbGbCtD
Repaglinide—PPARG—artery—type 2 diabetes mellitus	0.000589	0.0571	CbGeAlD
Repaglinide—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.000525	0.00193	CbGbCtD
Repaglinide—CYP3A4—Orlistat—type 2 diabetes mellitus	0.000503	0.00185	CbGbCtD
Repaglinide—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.000503	0.00185	CbGbCtD
Repaglinide—PPARG—endothelium—type 2 diabetes mellitus	0.000498	0.0482	CbGeAlD
Repaglinide—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.000476	0.00175	CbGbCtD
Repaglinide—KCNJ11—islet of Langerhans—type 2 diabetes mellitus	0.000403	0.039	CbGeAlD
Repaglinide—ABCC8—islet of Langerhans—type 2 diabetes mellitus	0.000371	0.0359	CbGeAlD
Repaglinide—CYP3A4—Glyburide—type 2 diabetes mellitus	0.000354	0.0013	CbGbCtD
Repaglinide—CYP3A4—Losartan—type 2 diabetes mellitus	0.000324	0.00119	CbGbCtD
Repaglinide—KCNJ11—cardiovascular system—type 2 diabetes mellitus	0.000291	0.0282	CbGeAlD
Repaglinide—PPARG—islet of Langerhans—type 2 diabetes mellitus	0.000283	0.0274	CbGeAlD
Repaglinide—KCNJ11—pancreas—type 2 diabetes mellitus	0.000283	0.0274	CbGeAlD
Repaglinide—ABCC8—cardiovascular system—type 2 diabetes mellitus	0.000268	0.026	CbGeAlD
Repaglinide—ABCC8—kidney—type 2 diabetes mellitus	0.000262	0.0254	CbGeAlD
Repaglinide—ABCC8—pancreas—type 2 diabetes mellitus	0.000261	0.0253	CbGeAlD
Repaglinide—SLCO1B1—kidney—type 2 diabetes mellitus	0.000232	0.0225	CbGeAlD
Repaglinide—PPARG—cardiovascular system—type 2 diabetes mellitus	0.000205	0.0198	CbGeAlD
Repaglinide—PPARG—kidney—type 2 diabetes mellitus	0.0002	0.0194	CbGeAlD
Repaglinide—PPARG—pancreas—type 2 diabetes mellitus	0.000199	0.0193	CbGeAlD
Repaglinide—PPARG—adipose tissue—type 2 diabetes mellitus	0.000181	0.0175	CbGeAlD
Repaglinide—SLCO1B1—liver—type 2 diabetes mellitus	0.000147	0.0142	CbGeAlD
Repaglinide—CYP2C8—kidney—type 2 diabetes mellitus	0.000132	0.0128	CbGeAlD
Repaglinide—PPARG—liver—type 2 diabetes mellitus	0.000127	0.0123	CbGeAlD
Repaglinide—ALB—liver—type 2 diabetes mellitus	0.000119	0.0115	CbGeAlD
Repaglinide—CYP3A4—kidney—type 2 diabetes mellitus	8.94e-05	0.00867	CbGeAlD
Repaglinide—CYP2C8—liver—type 2 diabetes mellitus	8.35e-05	0.00809	CbGeAlD
Repaglinide—CYP3A4—liver—type 2 diabetes mellitus	5.65e-05	0.00548	CbGeAlD
Repaglinide—Abdominal pain—Glimepiride—type 2 diabetes mellitus	5.14e-05	0.00108	CcSEcCtD
Repaglinide—Hypersensitivity—Glipizide—type 2 diabetes mellitus	5.14e-05	0.00108	CcSEcCtD
Repaglinide—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	5.13e-05	0.00108	CcSEcCtD
Repaglinide—Immune system disorder—Metformin—type 2 diabetes mellitus	5.12e-05	0.00108	CcSEcCtD
Repaglinide—Hypertension—Gliclazide—type 2 diabetes mellitus	5.1e-05	0.00107	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	5.07e-05	0.00107	CcSEcCtD
Repaglinide—Rhinitis—Losartan—type 2 diabetes mellitus	5.05e-05	0.00106	CcSEcCtD
Repaglinide—Hepatitis—Losartan—type 2 diabetes mellitus	5.04e-05	0.00106	CcSEcCtD
Repaglinide—Arthralgia—Gliclazide—type 2 diabetes mellitus	5.03e-05	0.00106	CcSEcCtD
Repaglinide—Chest pain—Gliclazide—type 2 diabetes mellitus	5.03e-05	0.00106	CcSEcCtD
Repaglinide—Rash—Rosiglitazone—type 2 diabetes mellitus	5.02e-05	0.00106	CcSEcCtD
Repaglinide—Constipation—Bromocriptine—type 2 diabetes mellitus	5.02e-05	0.00106	CcSEcCtD
Repaglinide—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	5.02e-05	0.00106	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	4.99e-05	0.00105	CcSEcCtD
Repaglinide—Headache—Rosiglitazone—type 2 diabetes mellitus	4.99e-05	0.00105	CcSEcCtD
Repaglinide—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	4.97e-05	0.00105	CcSEcCtD
Repaglinide—Erythema—Metformin—type 2 diabetes mellitus	4.94e-05	0.00104	CcSEcCtD
Repaglinide—Malnutrition—Metformin—type 2 diabetes mellitus	4.94e-05	0.00104	CcSEcCtD
Repaglinide—Pruritus—Glipizide—type 2 diabetes mellitus	4.93e-05	0.00104	CcSEcCtD
Repaglinide—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	4.92e-05	0.00104	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	4.89e-05	0.00103	CcSEcCtD
Repaglinide—Immune system disorder—Irbesartan—type 2 diabetes mellitus	4.84e-05	0.00102	CcSEcCtD
Repaglinide—Paraesthesia—Glyburide—type 2 diabetes mellitus	4.82e-05	0.00101	CcSEcCtD
Repaglinide—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	4.8e-05	0.00101	CcSEcCtD
Repaglinide—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	4.79e-05	0.00101	CcSEcCtD
Repaglinide—Palpitations—Valsartan—type 2 diabetes mellitus	4.79e-05	0.00101	CcSEcCtD
Repaglinide—Arrhythmia—Irbesartan—type 2 diabetes mellitus	4.78e-05	0.00101	CcSEcCtD
Repaglinide—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	4.78e-05	0.00101	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Ramipril—type 2 diabetes mellitus	4.77e-05	0.00101	CcSEcCtD
Repaglinide—Diarrhoea—Glipizide—type 2 diabetes mellitus	4.77e-05	0.001	CcSEcCtD
Repaglinide—Erythema multiforme—Losartan—type 2 diabetes mellitus	4.76e-05	0.001	CcSEcCtD
Repaglinide—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	4.74e-05	0.001	CcSEcCtD
Repaglinide—Palpitations—Orlistat—type 2 diabetes mellitus	4.74e-05	0.000998	CcSEcCtD
Repaglinide—Nausea—Rosiglitazone—type 2 diabetes mellitus	4.73e-05	0.000997	CcSEcCtD
Repaglinide—Dyspepsia—Glyburide—type 2 diabetes mellitus	4.72e-05	0.000995	CcSEcCtD
Repaglinide—Myocardial infarction—Ramipril—type 2 diabetes mellitus	4.72e-05	0.000994	CcSEcCtD
Repaglinide—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	4.72e-05	0.000994	CcSEcCtD
Repaglinide—Jaundice—Ramipril—type 2 diabetes mellitus	4.69e-05	0.000988	CcSEcCtD
Repaglinide—Skin disorder—Gliclazide—type 2 diabetes mellitus	4.68e-05	0.000986	CcSEcCtD
Repaglinide—Urinary tract infection—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000986	CcSEcCtD
Repaglinide—Urticaria—Bromocriptine—type 2 diabetes mellitus	4.66e-05	0.000982	CcSEcCtD
Repaglinide—Erythema—Irbesartan—type 2 diabetes mellitus	4.66e-05	0.000982	CcSEcCtD
Repaglinide—Malnutrition—Irbesartan—type 2 diabetes mellitus	4.66e-05	0.000982	CcSEcCtD
Repaglinide—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	4.64e-05	0.000977	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	4.63e-05	0.000976	CcSEcCtD
Repaglinide—Arthralgia—Valsartan—type 2 diabetes mellitus	4.62e-05	0.000973	CcSEcCtD
Repaglinide—Chest pain—Valsartan—type 2 diabetes mellitus	4.62e-05	0.000973	CcSEcCtD
Repaglinide—Pruritus—Glimepiride—type 2 diabetes mellitus	4.6e-05	0.00097	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	4.59e-05	0.000966	CcSEcCtD
Repaglinide—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	4.57e-05	0.000963	CcSEcCtD
Repaglinide—Chest pain—Orlistat—type 2 diabetes mellitus	4.56e-05	0.000961	CcSEcCtD
Repaglinide—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	4.55e-05	0.000959	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	4.53e-05	0.000955	CcSEcCtD
Repaglinide—Sinusitis—Ramipril—type 2 diabetes mellitus	4.52e-05	0.000951	CcSEcCtD
Repaglinide—Arrhythmia—Losartan—type 2 diabetes mellitus	4.5e-05	0.000948	CcSEcCtD
Repaglinide—Alopecia—Losartan—type 2 diabetes mellitus	4.45e-05	0.000938	CcSEcCtD
Repaglinide—Diarrhoea—Glimepiride—type 2 diabetes mellitus	4.45e-05	0.000938	CcSEcCtD
Repaglinide—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	4.44e-05	0.000935	CcSEcCtD
Repaglinide—Vomiting—Glipizide—type 2 diabetes mellitus	4.43e-05	0.000934	CcSEcCtD
Repaglinide—Oedema—Valsartan—type 2 diabetes mellitus	4.43e-05	0.000933	CcSEcCtD
Repaglinide—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	4.43e-05	0.000933	CcSEcCtD
Repaglinide—Rash—Glipizide—type 2 diabetes mellitus	4.4e-05	0.000926	CcSEcCtD
Repaglinide—Dermatitis—Glipizide—type 2 diabetes mellitus	4.39e-05	0.000925	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	4.39e-05	0.000925	CcSEcCtD
Repaglinide—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	4.39e-05	0.000924	CcSEcCtD
Repaglinide—Erythema—Losartan—type 2 diabetes mellitus	4.39e-05	0.000924	CcSEcCtD
Repaglinide—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	4.37e-05	0.000921	CcSEcCtD
Repaglinide—Oedema—Orlistat—type 2 diabetes mellitus	4.37e-05	0.000921	CcSEcCtD
Repaglinide—Headache—Glipizide—type 2 diabetes mellitus	4.37e-05	0.00092	CcSEcCtD
Repaglinide—Palpitations—Metformin—type 2 diabetes mellitus	4.36e-05	0.000919	CcSEcCtD
Repaglinide—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	4.33e-05	0.000913	CcSEcCtD
Repaglinide—Paraesthesia—Gliclazide—type 2 diabetes mellitus	4.33e-05	0.000911	CcSEcCtD
Repaglinide—Hepatitis—Ramipril—type 2 diabetes mellitus	4.32e-05	0.00091	CcSEcCtD
Repaglinide—Skin disorder—Valsartan—type 2 diabetes mellitus	4.3e-05	0.000906	CcSEcCtD
Repaglinide—Hypertension—Metformin—type 2 diabetes mellitus	4.26e-05	0.000898	CcSEcCtD
Repaglinide—Urticaria—Glyburide—type 2 diabetes mellitus	4.26e-05	0.000898	CcSEcCtD
Repaglinide—Oedema peripheral—Ramipril—type 2 diabetes mellitus	4.26e-05	0.000897	CcSEcCtD
Repaglinide—Skin disorder—Orlistat—type 2 diabetes mellitus	4.25e-05	0.000895	CcSEcCtD
Repaglinide—Back pain—Losartan—type 2 diabetes mellitus	4.24e-05	0.000894	CcSEcCtD
Repaglinide—Abdominal pain—Glyburide—type 2 diabetes mellitus	4.24e-05	0.000894	CcSEcCtD
Repaglinide—Dyspepsia—Gliclazide—type 2 diabetes mellitus	4.24e-05	0.000893	CcSEcCtD
Repaglinide—Chest pain—Metformin—type 2 diabetes mellitus	4.2e-05	0.000886	CcSEcCtD
Repaglinide—Headache—Pioglitazone—type 2 diabetes mellitus	4.18e-05	0.000881	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	4.18e-05	0.00088	CcSEcCtD
Repaglinide—Leukopenia—Irbesartan—type 2 diabetes mellitus	4.17e-05	0.000879	CcSEcCtD
Repaglinide—Visual impairment—Ramipril—type 2 diabetes mellitus	4.16e-05	0.000877	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	4.16e-05	0.000876	CcSEcCtD
Repaglinide—Nausea—Glipizide—type 2 diabetes mellitus	4.14e-05	0.000872	CcSEcCtD
Repaglinide—Vomiting—Glimepiride—type 2 diabetes mellitus	4.14e-05	0.000871	CcSEcCtD
Repaglinide—Vomiting—Sitagliptin—type 2 diabetes mellitus	4.12e-05	0.000869	CcSEcCtD
Repaglinide—Constipation—Gliclazide—type 2 diabetes mellitus	4.12e-05	0.000868	CcSEcCtD
Repaglinide—Rash—Glimepiride—type 2 diabetes mellitus	4.1e-05	0.000864	CcSEcCtD
Repaglinide—Dermatitis—Glimepiride—type 2 diabetes mellitus	4.1e-05	0.000863	CcSEcCtD
Repaglinide—Rash—Sitagliptin—type 2 diabetes mellitus	4.09e-05	0.000861	CcSEcCtD
Repaglinide—Dermatitis—Sitagliptin—type 2 diabetes mellitus	4.09e-05	0.000861	CcSEcCtD
Repaglinide—Erythema multiforme—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000861	CcSEcCtD
Repaglinide—Headache—Glimepiride—type 2 diabetes mellitus	4.08e-05	0.000859	CcSEcCtD
Repaglinide—Headache—Sitagliptin—type 2 diabetes mellitus	4.06e-05	0.000856	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	4.03e-05	0.00085	CcSEcCtD
Repaglinide—Oedema—Metformin—type 2 diabetes mellitus	4.03e-05	0.000849	CcSEcCtD
Repaglinide—Hypertension—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000848	CcSEcCtD
Repaglinide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	4.02e-05	0.000846	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	3.98e-05	0.00084	CcSEcCtD
Repaglinide—Paraesthesia—Valsartan—type 2 diabetes mellitus	3.97e-05	0.000837	CcSEcCtD
Repaglinide—Arthralgia—Irbesartan—type 2 diabetes mellitus	3.97e-05	0.000836	CcSEcCtD
Repaglinide—Chest pain—Irbesartan—type 2 diabetes mellitus	3.97e-05	0.000836	CcSEcCtD
Repaglinide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	3.95e-05	0.000833	CcSEcCtD
Repaglinide—Thrombocytopenia—Metformin—type 2 diabetes mellitus	3.95e-05	0.000831	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.00083	CcSEcCtD
Repaglinide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	3.94e-05	0.00083	CcSEcCtD
Repaglinide—Paraesthesia—Orlistat—type 2 diabetes mellitus	3.93e-05	0.000827	CcSEcCtD
Repaglinide—Leukopenia—Losartan—type 2 diabetes mellitus	3.93e-05	0.000827	CcSEcCtD
Repaglinide—Skin disorder—Metformin—type 2 diabetes mellitus	3.92e-05	0.000825	CcSEcCtD
Repaglinide—Immune system disorder—Ramipril—type 2 diabetes mellitus	3.9e-05	0.000822	CcSEcCtD
Repaglinide—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.9e-05	0.000821	CcSEcCtD
Repaglinide—Palpitations—Losartan—type 2 diabetes mellitus	3.88e-05	0.000817	CcSEcCtD
Repaglinide—Nausea—Glimepiride—type 2 diabetes mellitus	3.86e-05	0.000814	CcSEcCtD
Repaglinide—Arrhythmia—Ramipril—type 2 diabetes mellitus	3.86e-05	0.000813	CcSEcCtD
Repaglinide—Nausea—Sitagliptin—type 2 diabetes mellitus	3.85e-05	0.000812	CcSEcCtD
Repaglinide—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.85e-05	0.000811	CcSEcCtD
Repaglinide—Urticaria—Gliclazide—type 2 diabetes mellitus	3.83e-05	0.000806	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	3.82e-05	0.000805	CcSEcCtD
Repaglinide—Alopecia—Ramipril—type 2 diabetes mellitus	3.82e-05	0.000804	CcSEcCtD
Repaglinide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.81e-05	0.000802	CcSEcCtD
Repaglinide—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	3.8e-05	0.000801	CcSEcCtD
Repaglinide—Oedema—Irbesartan—type 2 diabetes mellitus	3.8e-05	0.000801	CcSEcCtD
Repaglinide—Pruritus—Glyburide—type 2 diabetes mellitus	3.8e-05	0.0008	CcSEcCtD
Repaglinide—Constipation—Valsartan—type 2 diabetes mellitus	3.79e-05	0.000797	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	3.78e-05	0.000796	CcSEcCtD
Repaglinide—Erythema—Ramipril—type 2 diabetes mellitus	3.76e-05	0.000792	CcSEcCtD
Repaglinide—Malnutrition—Ramipril—type 2 diabetes mellitus	3.76e-05	0.000792	CcSEcCtD
Repaglinide—Chest pain—Losartan—type 2 diabetes mellitus	3.73e-05	0.000787	CcSEcCtD
Repaglinide—Arthralgia—Losartan—type 2 diabetes mellitus	3.73e-05	0.000787	CcSEcCtD
Repaglinide—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.73e-05	0.000786	CcSEcCtD
Repaglinide—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	3.72e-05	0.000785	CcSEcCtD
Repaglinide—Rash—Bromocriptine—type 2 diabetes mellitus	3.7e-05	0.00078	CcSEcCtD
Repaglinide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.7e-05	0.000779	CcSEcCtD
Repaglinide—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.69e-05	0.000778	CcSEcCtD
Repaglinide—Headache—Bromocriptine—type 2 diabetes mellitus	3.68e-05	0.000775	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.67e-05	0.000774	CcSEcCtD
Repaglinide—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.67e-05	0.000773	CcSEcCtD
Repaglinide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.62e-05	0.000763	CcSEcCtD
Repaglinide—Paraesthesia—Metformin—type 2 diabetes mellitus	3.62e-05	0.000763	CcSEcCtD
Repaglinide—Anaphylactic shock—Losartan—type 2 diabetes mellitus	3.58e-05	0.000754	CcSEcCtD
Repaglinide—Oedema—Losartan—type 2 diabetes mellitus	3.58e-05	0.000754	CcSEcCtD
Repaglinide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.58e-05	0.000753	CcSEcCtD
Repaglinide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.55e-05	0.000748	CcSEcCtD
Repaglinide—Dyspepsia—Metformin—type 2 diabetes mellitus	3.55e-05	0.000748	CcSEcCtD
Repaglinide—Urticaria—Valsartan—type 2 diabetes mellitus	3.52e-05	0.000741	CcSEcCtD
Repaglinide—Thrombocytopenia—Losartan—type 2 diabetes mellitus	3.51e-05	0.000738	CcSEcCtD
Repaglinide—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.5e-05	0.000737	CcSEcCtD
Repaglinide—Nausea—Bromocriptine—type 2 diabetes mellitus	3.49e-05	0.000734	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.48e-05	0.000733	CcSEcCtD
Repaglinide—Urticaria—Orlistat—type 2 diabetes mellitus	3.47e-05	0.000732	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.47e-05	0.00073	CcSEcCtD
Repaglinide—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.46e-05	0.000728	CcSEcCtD
Repaglinide—Constipation—Metformin—type 2 diabetes mellitus	3.45e-05	0.000726	CcSEcCtD
Repaglinide—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.42e-05	0.00072	CcSEcCtD
Repaglinide—Vomiting—Glyburide—type 2 diabetes mellitus	3.41e-05	0.000719	CcSEcCtD
Repaglinide—Pruritus—Gliclazide—type 2 diabetes mellitus	3.41e-05	0.000718	CcSEcCtD
Repaglinide—Rash—Glyburide—type 2 diabetes mellitus	3.38e-05	0.000713	CcSEcCtD
Repaglinide—Dermatitis—Glyburide—type 2 diabetes mellitus	3.38e-05	0.000712	CcSEcCtD
Repaglinide—Leukopenia—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000709	CcSEcCtD
Repaglinide—Headache—Glyburide—type 2 diabetes mellitus	3.36e-05	0.000708	CcSEcCtD
Repaglinide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.35e-05	0.000705	CcSEcCtD
Repaglinide—Palpitations—Ramipril—type 2 diabetes mellitus	3.32e-05	0.0007	CcSEcCtD
Repaglinide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.3e-05	0.000694	CcSEcCtD
Repaglinide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.3e-05	0.000694	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.28e-05	0.000692	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.26e-05	0.000687	CcSEcCtD
Repaglinide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.26e-05	0.000687	CcSEcCtD
Repaglinide—Constipation—Irbesartan—type 2 diabetes mellitus	3.25e-05	0.000685	CcSEcCtD
Repaglinide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.22e-05	0.000679	CcSEcCtD
Repaglinide—Paraesthesia—Losartan—type 2 diabetes mellitus	3.21e-05	0.000677	CcSEcCtD
Repaglinide—Urticaria—Metformin—type 2 diabetes mellitus	3.2e-05	0.000675	CcSEcCtD
Repaglinide—Arthralgia—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000675	CcSEcCtD
Repaglinide—Chest pain—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000675	CcSEcCtD
Repaglinide—Nausea—Glyburide—type 2 diabetes mellitus	3.19e-05	0.000671	CcSEcCtD
Repaglinide—Abdominal pain—Metformin—type 2 diabetes mellitus	3.19e-05	0.000671	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.18e-05	0.00067	CcSEcCtD
Repaglinide—Dyspepsia—Losartan—type 2 diabetes mellitus	3.15e-05	0.000664	CcSEcCtD
Repaglinide—Pruritus—Valsartan—type 2 diabetes mellitus	3.13e-05	0.00066	CcSEcCtD
Repaglinide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.11e-05	0.000655	CcSEcCtD
Repaglinide—Pruritus—Orlistat—type 2 diabetes mellitus	3.09e-05	0.000652	CcSEcCtD
Repaglinide—Oedema—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000647	CcSEcCtD
Repaglinide—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000647	CcSEcCtD
Repaglinide—Vomiting—Gliclazide—type 2 diabetes mellitus	3.06e-05	0.000645	CcSEcCtD
Repaglinide—Constipation—Losartan—type 2 diabetes mellitus	3.06e-05	0.000645	CcSEcCtD
Repaglinide—Rash—Gliclazide—type 2 diabetes mellitus	3.04e-05	0.00064	CcSEcCtD
Repaglinide—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.03e-05	0.000639	CcSEcCtD
Repaglinide—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.03e-05	0.000638	CcSEcCtD
Repaglinide—Urticaria—Irbesartan—type 2 diabetes mellitus	3.02e-05	0.000637	CcSEcCtD
Repaglinide—Headache—Gliclazide—type 2 diabetes mellitus	3.02e-05	0.000636	CcSEcCtD
Repaglinide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.01e-05	0.000634	CcSEcCtD
Repaglinide—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.01e-05	0.000633	CcSEcCtD
Repaglinide—Diarrhoea—Orlistat—type 2 diabetes mellitus	2.99e-05	0.00063	CcSEcCtD
Repaglinide—Skin disorder—Ramipril—type 2 diabetes mellitus	2.98e-05	0.000628	CcSEcCtD
Repaglinide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.93e-05	0.000617	CcSEcCtD
Repaglinide—Nausea—Gliclazide—type 2 diabetes mellitus	2.86e-05	0.000603	CcSEcCtD
Repaglinide—Pruritus—Metformin—type 2 diabetes mellitus	2.85e-05	0.000601	CcSEcCtD
Repaglinide—Urticaria—Losartan—type 2 diabetes mellitus	2.84e-05	0.000599	CcSEcCtD
Repaglinide—Abdominal pain—Losartan—type 2 diabetes mellitus	2.83e-05	0.000596	CcSEcCtD
Repaglinide—Vomiting—Valsartan—type 2 diabetes mellitus	2.81e-05	0.000593	CcSEcCtD
Repaglinide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.8e-05	0.00059	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.8e-05	0.000589	CcSEcCtD
Repaglinide—Rash—Valsartan—type 2 diabetes mellitus	2.79e-05	0.000588	CcSEcCtD
Repaglinide—Dermatitis—Valsartan—type 2 diabetes mellitus	2.79e-05	0.000587	CcSEcCtD
Repaglinide—Vomiting—Orlistat—type 2 diabetes mellitus	2.78e-05	0.000586	CcSEcCtD
Repaglinide—Headache—Valsartan—type 2 diabetes mellitus	2.77e-05	0.000584	CcSEcCtD
Repaglinide—Diarrhoea—Metformin—type 2 diabetes mellitus	2.76e-05	0.000581	CcSEcCtD
Repaglinide—Rash—Orlistat—type 2 diabetes mellitus	2.76e-05	0.000581	CcSEcCtD
Repaglinide—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.76e-05	0.000581	CcSEcCtD
Repaglinide—Dermatitis—Orlistat—type 2 diabetes mellitus	2.76e-05	0.00058	CcSEcCtD
Repaglinide—Headache—Orlistat—type 2 diabetes mellitus	2.74e-05	0.000577	CcSEcCtD
Repaglinide—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.7e-05	0.000569	CcSEcCtD
Repaglinide—Pruritus—Irbesartan—type 2 diabetes mellitus	2.69e-05	0.000567	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.65e-05	0.000558	CcSEcCtD
Repaglinide—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.64e-05	0.000556	CcSEcCtD
Repaglinide—Nausea—Valsartan—type 2 diabetes mellitus	2.63e-05	0.000554	CcSEcCtD
Repaglinide—Constipation—Ramipril—type 2 diabetes mellitus	2.62e-05	0.000553	CcSEcCtD
Repaglinide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.6e-05	0.000548	CcSEcCtD
Repaglinide—Nausea—Orlistat—type 2 diabetes mellitus	2.6e-05	0.000547	CcSEcCtD
Repaglinide—Vomiting—Metformin—type 2 diabetes mellitus	2.56e-05	0.00054	CcSEcCtD
Repaglinide—Rash—Metformin—type 2 diabetes mellitus	2.54e-05	0.000535	CcSEcCtD
Repaglinide—Dermatitis—Metformin—type 2 diabetes mellitus	2.54e-05	0.000535	CcSEcCtD
Repaglinide—Pruritus—Losartan—type 2 diabetes mellitus	2.53e-05	0.000534	CcSEcCtD
Repaglinide—Headache—Metformin—type 2 diabetes mellitus	2.53e-05	0.000532	CcSEcCtD
Repaglinide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.51e-05	0.000529	CcSEcCtD
Repaglinide—Diarrhoea—Losartan—type 2 diabetes mellitus	2.45e-05	0.000516	CcSEcCtD
Repaglinide—Urticaria—Ramipril—type 2 diabetes mellitus	2.44e-05	0.000514	CcSEcCtD
Repaglinide—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.43e-05	0.000511	CcSEcCtD
Repaglinide—Vomiting—Irbesartan—type 2 diabetes mellitus	2.42e-05	0.00051	CcSEcCtD
Repaglinide—Rash—Irbesartan—type 2 diabetes mellitus	2.4e-05	0.000505	CcSEcCtD
Repaglinide—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.4e-05	0.000505	CcSEcCtD
Repaglinide—Nausea—Metformin—type 2 diabetes mellitus	2.39e-05	0.000504	CcSEcCtD
Repaglinide—Headache—Irbesartan—type 2 diabetes mellitus	2.38e-05	0.000502	CcSEcCtD
Repaglinide—Vomiting—Losartan—type 2 diabetes mellitus	2.28e-05	0.00048	CcSEcCtD
Repaglinide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.26e-05	0.000476	CcSEcCtD
Repaglinide—Nausea—Irbesartan—type 2 diabetes mellitus	2.26e-05	0.000476	CcSEcCtD
Repaglinide—Rash—Losartan—type 2 diabetes mellitus	2.26e-05	0.000476	CcSEcCtD
Repaglinide—Dermatitis—Losartan—type 2 diabetes mellitus	2.26e-05	0.000475	CcSEcCtD
Repaglinide—Headache—Losartan—type 2 diabetes mellitus	2.24e-05	0.000472	CcSEcCtD
Repaglinide—Pruritus—Ramipril—type 2 diabetes mellitus	2.17e-05	0.000458	CcSEcCtD
Repaglinide—Nausea—Losartan—type 2 diabetes mellitus	2.13e-05	0.000448	CcSEcCtD
Repaglinide—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.1e-05	0.000442	CcSEcCtD
Repaglinide—Vomiting—Ramipril—type 2 diabetes mellitus	1.95e-05	0.000411	CcSEcCtD
Repaglinide—Rash—Ramipril—type 2 diabetes mellitus	1.94e-05	0.000408	CcSEcCtD
Repaglinide—Dermatitis—Ramipril—type 2 diabetes mellitus	1.93e-05	0.000407	CcSEcCtD
Repaglinide—Headache—Ramipril—type 2 diabetes mellitus	1.92e-05	0.000405	CcSEcCtD
Repaglinide—Nausea—Ramipril—type 2 diabetes mellitus	1.82e-05	0.000384	CcSEcCtD
Repaglinide—PPARG—Metabolism—MTHFR—type 2 diabetes mellitus	2.33e-06	7.63e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	2.33e-06	7.61e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ALDOB—type 2 diabetes mellitus	2.32e-06	7.59e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—TGFB1—type 2 diabetes mellitus	2.32e-06	7.58e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	2.31e-06	7.57e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ALDOB—type 2 diabetes mellitus	2.3e-06	7.54e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—ALB—type 2 diabetes mellitus	2.3e-06	7.53e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PPARA—type 2 diabetes mellitus	2.29e-06	7.49e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PRKCB—type 2 diabetes mellitus	2.27e-06	7.44e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3R1—type 2 diabetes mellitus	2.27e-06	7.43e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—NOS3—type 2 diabetes mellitus	2.27e-06	7.43e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	2.26e-06	7.4e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	2.25e-06	7.37e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—NOS2—type 2 diabetes mellitus	2.25e-06	7.35e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GNB3—type 2 diabetes mellitus	2.24e-06	7.33e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.24e-06	7.33e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	2.24e-06	7.33e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—HMOX1—type 2 diabetes mellitus	2.23e-06	7.3e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—AGT—type 2 diabetes mellitus	2.22e-06	7.25e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	2.21e-06	7.22e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3R1—type 2 diabetes mellitus	2.2e-06	7.2e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—NOS3—type 2 diabetes mellitus	2.2e-06	7.2e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CAT—type 2 diabetes mellitus	2.2e-06	7.2e-05	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	2.2e-06	7.19e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	2.19e-06	7.18e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—SERPINE1—type 2 diabetes mellitus	2.19e-06	7.17e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	2.18e-06	7.14e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CALM1—type 2 diabetes mellitus	2.18e-06	7.13e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—APOE—type 2 diabetes mellitus	2.17e-06	7.11e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	2.17e-06	7.1e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GLP1R—type 2 diabetes mellitus	2.16e-06	7.05e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—APOA1—type 2 diabetes mellitus	2.15e-06	7.03e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GLP1R—type 2 diabetes mellitus	2.14e-06	7.01e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—APOB—type 2 diabetes mellitus	2.14e-06	6.99e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	2.09e-06	6.83e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	2.09e-06	6.83e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTM1—type 2 diabetes mellitus	2.08e-06	6.8e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTGS2—type 2 diabetes mellitus	2.08e-06	6.79e-05	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	2.06e-06	6.75e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—LPL—type 2 diabetes mellitus	2.04e-06	6.68e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—IL6—type 2 diabetes mellitus	2.04e-06	6.67e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	2.01e-06	6.59e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	2.01e-06	6.59e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	2.01e-06	6.59e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	2.01e-06	6.59e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	2.01e-06	6.59e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTGS2—type 2 diabetes mellitus	2.01e-06	6.59e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC2A2—type 2 diabetes mellitus	2.01e-06	6.58e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC2A2—type 2 diabetes mellitus	2e-06	6.55e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ADCY5—type 2 diabetes mellitus	2e-06	6.54e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IGF1—type 2 diabetes mellitus	1.99e-06	6.52e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GPX1—type 2 diabetes mellitus	1.99e-06	6.51e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—AKT2—type 2 diabetes mellitus	1.99e-06	6.51e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CPT1A—type 2 diabetes mellitus	1.97e-06	6.45e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTR—type 2 diabetes mellitus	1.97e-06	6.45e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CPT1A—type 2 diabetes mellitus	1.96e-06	6.41e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTR—type 2 diabetes mellitus	1.96e-06	6.41e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.95e-06	6.38e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CD36—type 2 diabetes mellitus	1.94e-06	6.34e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NAMPT—type 2 diabetes mellitus	1.93e-06	6.33e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NAMPT—type 2 diabetes mellitus	1.92e-06	6.29e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.92e-06	6.29e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HBA1—type 2 diabetes mellitus	1.92e-06	6.29e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—LIPC—type 2 diabetes mellitus	1.92e-06	6.29e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GCK—type 2 diabetes mellitus	1.92e-06	6.29e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.91e-06	6.26e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.91e-06	6.25e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—LIPC—type 2 diabetes mellitus	1.91e-06	6.25e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HBA1—type 2 diabetes mellitus	1.91e-06	6.25e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GCK—type 2 diabetes mellitus	1.91e-06	6.25e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP11A1—type 2 diabetes mellitus	1.91e-06	6.25e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP11A1—type 2 diabetes mellitus	1.9e-06	6.21e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SERPINE1—type 2 diabetes mellitus	1.89e-06	6.19e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—AKT1—type 2 diabetes mellitus	1.88e-06	6.15e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC9A1—type 2 diabetes mellitus	1.87e-06	6.14e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC9A1—type 2 diabetes mellitus	1.86e-06	6.1e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—INS—type 2 diabetes mellitus	1.86e-06	6.07e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CETP—type 2 diabetes mellitus	1.85e-06	6.07e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CETP—type 2 diabetes mellitus	1.84e-06	6.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.84e-06	6.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.84e-06	6.03e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—MTHFR—type 2 diabetes mellitus	1.84e-06	6.01e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3R1—type 2 diabetes mellitus	1.81e-06	5.91e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—NOS3—type 2 diabetes mellitus	1.81e-06	5.91e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPARA—type 2 diabetes mellitus	1.8e-06	5.9e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.8e-06	5.88e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—AGT—type 2 diabetes mellitus	1.75e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.73e-06	5.66e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PSMD6—type 2 diabetes mellitus	1.72e-06	5.64e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SNAP25—type 2 diabetes mellitus	1.72e-06	5.64e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SREBF1—type 2 diabetes mellitus	1.72e-06	5.64e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CALM1—type 2 diabetes mellitus	1.72e-06	5.62e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PSMD6—type 2 diabetes mellitus	1.71e-06	5.61e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SNAP25—type 2 diabetes mellitus	1.71e-06	5.61e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SREBF1—type 2 diabetes mellitus	1.71e-06	5.61e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.71e-06	5.6e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.71e-06	5.6e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.71e-06	5.6e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—APOE—type 2 diabetes mellitus	1.71e-06	5.6e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—ALB—type 2 diabetes mellitus	1.7e-06	5.57e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CTGF—type 2 diabetes mellitus	1.69e-06	5.53e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—APOA1—type 2 diabetes mellitus	1.69e-06	5.53e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CTGF—type 2 diabetes mellitus	1.68e-06	5.5e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HMGCR—type 2 diabetes mellitus	1.68e-06	5.49e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HMGCR—type 2 diabetes mellitus	1.67e-06	5.45e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.65e-06	5.41e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.64e-06	5.38e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.64e-06	5.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.64e-06	5.37e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ADRA2A—type 2 diabetes mellitus	1.64e-06	5.37e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ADRA2A—type 2 diabetes mellitus	1.63e-06	5.34e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NOS3—type 2 diabetes mellitus	1.63e-06	5.32e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3R1—type 2 diabetes mellitus	1.63e-06	5.32e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	1.61e-06	5.27e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.58e-06	5.17e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.58e-06	5.17e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP2E1—type 2 diabetes mellitus	1.58e-06	5.16e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	1.57e-06	5.13e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP1A2—type 2 diabetes mellitus	1.56e-06	5.1e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC2A1—type 2 diabetes mellitus	1.56e-06	5.1e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.55e-06	5.08e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	1.55e-06	5.07e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	1.55e-06	5.07e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.53e-06	5e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.53e-06	5e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.53e-06	5e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP3A4—type 2 diabetes mellitus	1.52e-06	4.97e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.51e-06	4.95e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	1.51e-06	4.94e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.5e-06	4.92e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GCG—type 2 diabetes mellitus	1.49e-06	4.89e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC2A4—type 2 diabetes mellitus	1.49e-06	4.89e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPARG—type 2 diabetes mellitus	1.49e-06	4.87e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTGS2—type 2 diabetes mellitus	1.49e-06	4.87e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	1.49e-06	4.86e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GCG—type 2 diabetes mellitus	1.49e-06	4.86e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—INS—type 2 diabetes mellitus	1.46e-06	4.78e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.44e-06	4.7e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.34e-06	4.4e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ALB—type 2 diabetes mellitus	1.34e-06	4.38e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SRC—type 2 diabetes mellitus	1.34e-06	4.37e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	1.3e-06	4.26e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.3e-06	4.25e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.3e-06	4.25e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.3e-06	4.25e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.3e-06	4.25e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GNB3—type 2 diabetes mellitus	1.29e-06	4.21e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.29e-06	4.21e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HMOX1—type 2 diabetes mellitus	1.28e-06	4.19e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NOS3—type 2 diabetes mellitus	1.28e-06	4.19e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.28e-06	4.19e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GNB3—type 2 diabetes mellitus	1.28e-06	4.19e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.28e-06	4.19e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	1.27e-06	4.17e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	1.26e-06	4.14e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CAT—type 2 diabetes mellitus	1.26e-06	4.12e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.24e-06	4.07e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	1.23e-06	4.02e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—APOB—type 2 diabetes mellitus	1.22e-06	3.99e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	1.19e-06	3.91e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	1.19e-06	3.91e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	1.19e-06	3.89e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	1.17e-06	3.84e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTGS2—type 2 diabetes mellitus	1.17e-06	3.83e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—LPL—type 2 diabetes mellitus	1.17e-06	3.81e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.16e-06	3.79e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	1.15e-06	3.76e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	1.14e-06	3.74e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	1.14e-06	3.73e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GPX1—type 2 diabetes mellitus	1.14e-06	3.72e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	1.11e-06	3.65e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CD36—type 2 diabetes mellitus	1.11e-06	3.62e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	1.1e-06	3.6e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	1.09e-06	3.58e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.08e-06	3.53e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.06e-06	3.46e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.06e-06	3.46e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	1.06e-06	3.45e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	1.05e-06	3.43e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—AKT1—type 2 diabetes mellitus	1.04e-06	3.42e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.04e-06	3.4e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	1.04e-06	3.39e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.03e-06	3.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.03e-06	3.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.03e-06	3.37e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPARA—type 2 diabetes mellitus	1.03e-06	3.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.02e-06	3.35e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—AKT1—type 2 diabetes mellitus	1.01e-06	3.31e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.01e-06	3.29e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	1e-06	3.28e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—AGT—type 2 diabetes mellitus	9.97e-07	3.26e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	9.95e-07	3.26e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	9.86e-07	3.23e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	9.83e-07	3.22e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CALM1—type 2 diabetes mellitus	9.8e-07	3.21e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—APOE—type 2 diabetes mellitus	9.77e-07	3.2e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	9.71e-07	3.18e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—APOA1—type 2 diabetes mellitus	9.66e-07	3.16e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—AKT1—type 2 diabetes mellitus	9.62e-07	3.15e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	9.25e-07	3.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	9.25e-07	3.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	9.25e-07	3.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	9.08e-07	2.97e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	9e-07	2.94e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	8.8e-07	2.88e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	8.56e-07	2.8e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPARG—type 2 diabetes mellitus	8.51e-07	2.79e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	8.46e-07	2.77e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	8.39e-07	2.75e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	8.36e-07	2.74e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	8.36e-07	2.74e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—INS—type 2 diabetes mellitus	8.35e-07	2.73e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	8.3e-07	2.72e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	8.02e-07	2.62e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	8.02e-07	2.62e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	7.7e-07	2.52e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—AKT1—type 2 diabetes mellitus	7.48e-07	2.45e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	7.36e-07	2.41e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	7.36e-07	2.41e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	7.32e-07	2.4e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NOS3—type 2 diabetes mellitus	7.32e-07	2.4e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	6.91e-07	2.26e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.91e-07	2.26e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	6.88e-07	2.25e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	6.79e-07	2.22e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	6.73e-07	2.2e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	6.69e-07	2.19e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	6.59e-07	2.16e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	6.41e-07	2.1e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	6.29e-07	2.06e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	6.16e-07	2.02e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	6.14e-07	2.01e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	5.98e-07	1.96e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	5.9e-07	1.93e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—AKT1—type 2 diabetes mellitus	5.89e-07	1.93e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	5.66e-07	1.85e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	5.56e-07	1.82e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	5.38e-07	1.76e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	5.29e-07	1.73e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	5.27e-07	1.73e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	5.21e-07	1.71e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	4.59e-07	1.5e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	4.51e-07	1.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	4.13e-07	1.35e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.95e-07	1.29e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.95e-07	1.29e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	3.61e-07	1.18e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	3.38e-07	1.11e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—AKT1—type 2 diabetes mellitus	3.36e-07	1.1e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.82e-07	5.94e-06	CbGpPWpGaD
